- Third quarter net loss narrows on higher revenue due to Roche milestone -
BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.
Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."
Results for Third Quarter 2008
InterMune reported total revenue in the third quarter of 2008 of $23.3
million, compared with total revenue of $11.4 million in the third quarter
of 2007. Total revenue in the third quarter of 2008 primarily consisted of
revenue from the collaboration with Roche for the development of protease
inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the
third quarter of 2008, compared with $0.8 million in the same quarter of
2007. Third quarter 2008 collaborati
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved